Related Experiment Video
Updated: Jan 16, 2026
Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation
Published on: October 25, 2024
CTLA-4 nanovesicles disrupt dendritic cell-driven CD8 T cell priming for myocardial infarction therapy
Shengnan Wang1, Mengting Li1, Han Shen1
1Department of Cardiovascular Surgery of the First Affiliated Hospital & Institute for Cardiovascular Science, Suzhou Medical College of Soochow University, Soochow University, Suzhou, China.
Insights
Engineered vesicles delivering cytotoxic T-lymphocyte antigen 4 (CTLA-4) reduce inflammation after myocardial infarction (MI). This novel therapy supports heart repair by modulating T-cell responses via dendritic cells (DCs).
Area of Science:
- Immunology
- Cardiology
- Biotechnology
Background:
- Myocardial infarction (MI) causes significant inflammation, worsening cardiac dysfunction and disease.
- Current therapies are limited by excessive inflammation.
- T-lymphocyte receptors like CTLA-4 and CD28 regulate T-cell activation, impacting immune responses.
Purpose of the Study:
- To engineer mannosylated CTLA-4-presenting small extracellular vesicles (CM@sEVs) for targeted MI therapy.
- To investigate the mechanism of CM@sEVs in modulating T-cell responses and promoting myocardial repair.
- To offer a precise and stable therapeutic strategy for ischemic cardiomyopathy.
Main Methods:
- Engineering of CM@sEVs for targeted delivery of CTLA-4.
- Disruption of CD80/86-CD28 costimulatory signaling by CM@sEVs.
- Assessment of CM@sEVs' effect on dendritic cell (DC)-driven CD8+ T cell priming in vivo.
- Evaluation of CM@sEVs' impact on ischemic immunopathology and myocardial repair.
Main Results:
- CM@sEVs effectively disrupted CD80/86-CD28 costimulatory signaling.
- CM@sEVs mitigated DC-driven CD8+ T cell priming, reducing ischemic immunopathology.
- The engineered vesicles supported myocardial repair post-MI.
- CM@sEVs demonstrated a unique DC-dependent mechanism for reshaping in vivo T-cell dynamics.
Conclusions:
- CM@sEVs represent a novel therapeutic approach for MI by modulating T-cell responses.
- This strategy offers a precise and stable method for treating ischemic cardiomyopathy.
- Targeting DC-dependent mechanisms provides a distinct advantage over existing T-cell modulatory therapies.
Abstract:
Myocardial infarction (MI) remains a formidable global health challenge, as current therapies are hindered by excessive inflammation that exacerbates cardiac dysfunction and accelerates disease progression. Cytotoxic T-lymphocyte antigen 4 (CTLA-4) and CD28 are T-lymphocyte receptors with opposing roles in T-cell activation: CD28 binding to CD80/CD86 ligands on dendritic cells (DCs) mediates co-stimulation, whereas CTLA-4 engagement delivers inhibitory signals. In our present study, mannosylated cytotoxic T-lymphocyte antigen 4 (CTLA-4)-presenting small extracellular vesicles (CM@sEVs) were engineered for targeted MI therapy. By disrupting the CD80/86-CD28 costimulatory signaling, these CM@sEVs counteract dendritic cell (DC)-driven CD8+ T cell priming, thereby mitigating ischemic immunopathology while supporting myocardial repair. Notably, distinct from existing T-cell modulatory therapies, our CM@sEVs uniquely reshape in vivo T-cell dynamics directly through DC-dependent mechanisms, offering a precise and stable strategy for ischemic cardiomyopathy.
